论文部分内容阅读
用双抗体夹心酶联免疫吸附法检测了１６２例血液病病人血清可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）水平。结果表明，急、慢性白血病（ＡＬ，ＣＬ）、何杰金氏淋巴瘤和骨髓增生异常综合症（ＭＤＳ）组血清ｓＩＬ－２Ｒ水平显著高于缺铁性贫血、慢性再生障碍性贫血及正常对照组（Ｐ＜０．０１）。而且血清ｓＩＬ－２Ｒ水平与病情变化有关，完全缓解（ＣＲ）的ＡＬ病人血清ｓＩＬ－２Ｒ水平较治疗前明显降低，其水平高低与维持缓解的时间有关。ＭＤＳ亚型中预后差的转化中原始细胞过多的难治性贫血病人血清ｓＩＬ－２Ｒ水平明显高于难治性贫血及难治性贫血伴环形铁粒幼红细胞者，而与急性非淋巴细胞性白血病水平无显著差异（Ｐ＞０．０５）。提示高水平的血清ｓＩＬ－２Ｒ与造血系统恶性肿瘤肿及瘤细胞负荷有密切关系，动态观察其血清ｓＩＬ－２Ｒ水平的变化有助于临床监护、疗效观察及预后估计，亦对探讨免疫功能异常与恶性血液病的发生、发展的关系有重要意义。
Serum soluble interleukin 2 receptor (sIL-2R) levels were measured in 162 patients with hematological diseases by double antibody sandwich enzyme-linked immunosorbent assay. The results showed that serum sIL-2R levels in acute, chronic leukemia (AL, CL), Hodgkin’s lymphoma and myelodysplastic syndromes (MDS) were significantly higher than those in patients with iron deficiency anemia, chronic aplastic anemia and normal controls Group (P <0.01). Moreover, the level of sIL-2R in serum is related to the change of the disease. The level of sIL-2R in patients with complete remission (CR) is significantly lower than that before treatment, and the level of serum sIL-2R is related to the time of maintaining remission. In patients with poor prognosis of MDS subtypes, serum sIL-2R level is significantly higher in patients with refractory anemia than in patients with refractory anemia and refractory anemia, whereas patients with acute non-lymphocytic There was no significant difference in leukemia (P> 0.05). These results suggest that high level of serum sIL-2R is closely related to hematopoietic malignant tumor and tumor cell load. Dynamic observation of serum sIL-2R level is helpful for clinical monitoring, curative effect observation and prognosis estimation. And the occurrence and development of hematologic malignancies is of great significance.